Clinical Research Directory
Browse clinical research sites, groups, and studies.
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Sponsor: Aaron Cook
Summary
The proposed study aims to evaluate the CNS penetration of telavancin in a critically ill population using cerebrospinal fluid (CSF) drawn from external ventricular drains (EVDs). Patients with EVDs were chosen as the target population because they frequently require prolonged admission to the intensive care unit and drainage of CSF in order to prevent hydrocephalus. The estimated sample size is 20 subjects. This is a prospective cohort of patients with SAH. Patients will be included if they have an in-dwelling EVD, aged 18-85 years old. Subjects will receive telavancin 10mg/kg (maximum 1000mg) every 24 hours for 3 consecutive doses. Serial serum and CSF samples will be obtained. An 8-hour urine collection will be completed on study day 2 in order to define the patient's measured creatinine clearance.
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-07-02
Completion Date
2026-12
Last Updated
2025-12-26
Healthy Volunteers
No
Conditions
Interventions
Telavancin Injection
Telavancin 10mg/kg (maximum 1000mg) administered intravenously over 60 minutes (through a central venous catheter whenever available).
Locations (1)
University of Kentucky
Lexington, Kentucky, United States